Sydney Jennings

Your daily dose of the clinical news you may have missed.

Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.

Your daily dose of the clinical news you may have missed.

Dr Khanna urges early screening for cardiometabolic risk in patients with obesity and highlights the role of primary care in prevention and education.

ENDO 2025. People with inconsistent access to GLP-1 medications still achieved clinically significant weight loss when therapy was combined with lifestyle changes and coaching.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.

Bayer's elinzanetant gains UK approval as the first dual-action, nonhormonal treatment for menopausal symptoms.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.

The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.

Your daily dose of the clinical news you may have missed.

Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.